Clinical Trial Update: Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL [Phase 2]

View source ↗

Summary

A Phase II trial is evaluating a three-drug combination (golidocitinib, pegaspargase, and a PD-1 antibody) as first-line therapy for advanced extranodal NK/T-ce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Nk T-cell Lymphoma Nasal Type

Drugs mentioned

• Golidocitinib (golidocitinib)
• PD-1 antibody (PD-1 inhibitor)
• Pegaspargase (pegaspargase)

Snippet

Sponsor: LIANG WANG | Conditions: NK T-Cell Lymphoma | Phase 2 | Status: NOT_YET_RECRUITING